GlassScriptPhysician profile
Rohit V Mahajani
NPI 1194820233
$1,782.79
in general payments reported to CMS, 2019-2025
16 companies · $367 in 2025
The $367 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.70 · 2020: $107 · 2021: $223 · 2022: $385 · 2023: $319 · 2024: $369 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989 · Education: $66.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.20 |
| Education | $66.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $890.54 | 2021-2025 | |
| Braintree Laboratories, INC. | $423.08 | 2020-2022 | |
| Pfizer INC. | $70.53 | 2019-2022 | |
| Celltrion USA INC. | $66.13 | 2023-2024 | Zymfentra, Yuflyma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.08 | 2024 | Trulance |
| Ipsen Biopharmaceuticals, INC | $59.99 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $53.19 | 2025 | |
| Lucid Diagnostics INC. | $42.89 | 2021 | |
| Boston Scientific Corporation | $25.66 | 2023 | Watchman Flx |
| Organon LLC | $21.83 | 2025 | Nexplanon |
| Laborie Medical Technologies Corp. | $19.64 | 2024 | Solar Uroflow System |
| Madrigal Pharmaceuticals | $15.33 | 2024 | Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $13.98 | 2024 | Entyvio |
| Lilly USA, LLC | $13.71 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $6.21 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Mahajani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.